Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study

References

• 20191218_144638_wp_factsheet_en.pdf [Internet]. [cited 2020 Feb 24]. Available from: https://diabetesatlas.org/upload/resources/material/20191218_144638_wp_factsheet_en.pdf.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the european association for the study of diabetes. Diabetologia. 2015;58(3):429–442.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract. 2017;23(2):207–238.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a Patient-Centered approach: Update to a position statement of the American diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas [Internet]. [cited 2020 Apr 15]. Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html.
   Google Scholar
• Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellit. 2021;13:315–409.
   Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet Lond Engl. 2008;371(9626):1753–1760.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and Meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28–34.
   PubMed Web of Science ®Google Scholar
• Weng J, Ji L, Jia W, Chinese Diabetes Society, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32(5):442–458.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Global guideline for type 2 diabetes. [Internet]. 2012. [cited 2020 Feb 12]. Available from: http://www.idf.org/guideline-type-2-diabetes.
   Google Scholar
• Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66(1):31–49.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie Y-J, Meng D-D, et al. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):37.
   PubMedGoogle Scholar
• He X, Chen L, Wang K, et al. Insulin adherence and persistence among chinese patients with type 2 diabetes: a retrospective database analysis. PPA. 2017;ume 11:237–245.
   Google Scholar
• Yang W, Lv X, Li Q, et al. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 2012;28(4):533–541.
   PubMed Web of Science ®Google Scholar
• Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health-Syst Pharm AJHP off J Am Soc Health-Syst Pharm. 2006;63(24):2473–2482.
   PubMed Web of Science ®Google Scholar
• Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259.
   PubMed Web of Science ®Google Scholar
• Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract. 2007;61(12):2009–2018.
   PubMed Web of Science ®Google Scholar
• Davies M, Sinnassamy P, Storms F, et al. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes Sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 2008;79(2):368–375.
   PubMed Web of Science ®Google Scholar
• Schiel R, Müller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the switch pilot study. Exp Clin Endocrinol Diabetes. 2007;115(10):627–633.
   PubMed Web of Science ®Google Scholar
• Sharplin P, Gordon J, Peters JRJ, et al. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis. Cardiovasc Diabetol. 2009;8:9.
   Web of Science ®Google Scholar
• Petrovski G, Gjergji D, Grbic A, et al. Switching from pre-mixed insulin to regimens with insulin glargine in type 2 diabetes: a prospective, observational study of data from adriatic countries. Diabetes Ther. 2018;9(4):1657–1668.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Storms F, Tits J, et al. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin Belg. 2013;68(1):28–33.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhao J, Yang W, on behalf of the Lantus Registry Study Group Glycemic control and safety in chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. Diabetes Metab Res Rev. 2017;33(3):e2863.
   Web of Science ®Google Scholar
• Bu S, Guo X-H, Yang W-Y[, et al. Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen. ]. Zhonghua Yi Xue Za Zhi. 2007;87:3115–3118.
   PubMedGoogle Scholar
• Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803–817.
   PubMed Web of Science ®Google Scholar
• C M K, Patil S. Urinary c-peptide and urine C-peptide/creatinine ratio (ucpcr) are possible predictors of endogenous insulin secretion in t2dm subjects - a randomized study. Int J Pharma Bio Sci. 2016;7(4):443–446.
   PubMedGoogle Scholar
• Leighton E, Sainsbury CA, Jones GA. Practical review of C-Peptide testing in diabetes. Diabetes Ther. 2017;8(3):475–487.
   PubMed Web of Science ®Google Scholar
• Wang Y-B, Wang S, Bai R, et al. Efficacy of switching from premixed insulin to insulin glargine regimen in type 2 diabetes mellitus patients with different islet functions. Mol Med Rep. 2014;10(2):1096–1102.
   PubMed Web of Science ®Google Scholar
• Bu S, Guo X, Yang W, et al. Analysis of the clinical characteristics of type 2 diabetic patients who converted from premixed insulin to basal insulin combined with oral hypoglycemic drugs. Chin Med J (Engl). 2007;87:3115–3118.
   Google Scholar
• Gómez-Peralta F, Abreu C, Mora-Navarro G, et al. Switching from premixed insulin to basal insulin analogue for type 2 diabetes and role of dipeptidyl peptidase-4 inhibitors. Exp Clin Endocrinol Diabetes. 2018;126(05):268–276.
   PubMedGoogle Scholar
• Landgraf W, Owens DR, Frier BM, et al. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes Obes Metab. 2020;22(3):315–323.
   PubMed Web of Science ®Google Scholar
• Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice [Internet]. Routledge CRC Press. [cited 2022 Apr 25]. Available from: https://www.routledge.com/Handbook-of-Psychology-and-Diabetes-A-Guide-to-Psychological-Measurement/Bradley/p/book/9783718655625.
   Google Scholar
• Defining and Reporting Hypoglycemia in Diabetes | Diabetes Care [Internet]. [cited 2020 Apr 14]. Available from: https://care.diabetesjournals.org/content/28/5/1245.
   Google Scholar
• Steiner DF, Cunningham D, Spigelman L, et al. Insulin biosynthesis: evidence for a precursor. Science. 1967;157(3789):697–700.
   PubMed Web of Science ®Google Scholar
• Yosten GLC, Maric-Bilkan C, Luppi P, et al. Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014;307(11):E955–968.
   PubMed Web of Science ®Google Scholar
• Landin-Olsson M, Nilsson KO, Lernmark A, et al. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia. 1990;33(9):561–568.
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand. 1981;210(3):153–156.
   PubMedGoogle Scholar
• Safai N, Ali A, Rossing P, et al. Stratification of type 2 diabetes based on routine clinical markers. Diabetes Res Clin Pract. 2018;141:275–283.
   PubMed Web of Science ®Google Scholar
• Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369.
   PubMed Web of Science ®Google Scholar
• Woo V, Shestakova MV, Ørskov C, et al. Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract. 2008;62(12):1935–1942.
   PubMed Web of Science ®Google Scholar
• Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and Meta-analyses. Diabetologia. 2009;52(10):1990–2000.
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, et al. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29(6):1254–1270.
   Google Scholar
• Strojek K, Bebakar WMW, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin. 2009;25(12):2887–2894.
   PubMed Web of Science ®Google Scholar
• Ji L, Feng B, Su Q. The safety and efficacy of initiating insulin therapy in chinese patients with type 2 diabetes mellitus inadequately controlled with previous oral antidiabetic drugs. Chin J Diabetes. 2011;19:746–791.
   Google Scholar